Last updated: February 26, 2026
What Is NDC 00143-3142?
NDC 00143-3142 refers to a specific branded drug listed in the National Drug Code database. According to available data, this NDC corresponds to EYLEA (aflibercept) Injection, a biologic used primarily for treating retinal diseases, including age-related macular degeneration (AMD), diabetic macular edema (DME), and recurrent wet age-related macular degeneration.
EYLEA (aflibercept) was developed by Regeneron Pharmaceuticals. The drug received FDA approval in 2011. It is administered via intravitreal injection, typically every 8 to 12 weeks.
Market Overview and Size
Therapeutic Market
The ophthalmology biologic market is driven by the prevalence of retinal diseases. Key data:
- The AMD treatment market was valued at approximately USD 3.2 billion in 2022 and is projected to grow at a compound annual growth rate (CAGR) of around 4.7% until 2030[1].
- The diabetic retinopathy market is forecasted to reach USD 1.8 billion by 2027, growing at a CAGR of 5.2%[2].
Key Competitors
- Lucentis (ranibizumab): Marketed by Genentech/Roche; comparable efficacy.
- Beovu (brolucizumab)): Marketed by Novartis; provides extended dosing intervals.
- Faricimab (Vabysmo)): Marketed by Genentech; dual mechanism targeting VEGF-A and angiopoietin-2.
Market Share
EYLEA maintains approximately 65-70% share in wet AMD, owing to earlier FDA approval and broader dosing flexibility. Competition has incrementally eroded its dominance but remains the leading biologic in this niche.
Uptake and Adoption Trends
- Increasing global adoption with expanding indications outside the U.S., notably in Europe and Asia.
- Growing preference for less frequent dosing regimens (e.g., every 12 weeks), which EYLEA offers.
- Slight decline in new patient initiation in mature markets due to monotherapy or biosimilar entry.
Price Dynamics and Projections
Current Pricing
Average wholesale prices (AWP):
| Item |
Price (USD) per dose |
Notes |
| EYLEA (aflibercept) |
$1,800 – $2,100 |
Per injection in the U.S. |
Pricing varies by region, payer negotiations, and formulary placement. The U.S. retail price remains relatively stable but is subject to discounts and rebates.
Competitive Pricing Benchmarks
- Ranibizumab (Lucentis): $1,850 – $2,000 per dose.
- Brolucizumab (Beovu): $1,650 – $2,050 per dose.
- Faricimab (Vabysmo): approximately $1,950 per injection.
Price Trajectory Forecast (2023–2028)
- Stability expected due to manufacturing complexity and patent protections extending to at least 2027.
- Potential downward pressure from biosimilar entrants starting in 2025, especially if biosimilar versions of EYLEA enter the market in Europe and Asia.
- Pricing adjustments driven by payer negotiations, value-based pricing, and formulary decisions.
Impact of Biosimilars and Generics
- Biosimilar versions are under development, potentially launching between 2025 and 2027.
- Competitors may price biosimilars 20-30% lower than originator products, reducing EYLEA’s market share and price.
Revenue Implications
- Global revenues for EYLEA are estimated to reach USD 4 billion annually by 2023.
- For the U.S. alone, revenues approximate USD 2.5 billion, with growth potential constrained by biosimilar competition.
Regulatory and Patent Landscape
- Patent protections for EYLEA extend into 2027, with some pediatric exclusivities possibly prolonging market exclusivity until 2029.
- Patent litigations and potential biosimilar approvals pose risks to pricing and market share beyond 2025.
Strategic Considerations for Market Players
- Manufacturers should follow biosimilar development closely.
- Payers will likely negotiate for price reductions, especially as biosimilars gain approval.
- Investment in formulation improvements or extended dosing could sustain product value amid biosimilar entry.
Key Takeaways
- NDC 00143-3142 corresponds to EYLEA, a dominant biologic for retinal diseases.
- The market is growing steadily, but biosimilar competition is imminent.
- Current U.S. wholesale price is approximately USD 1,800–2,100 per dose.
- Prices are expected to stabilize through 2024, with potential declines starting in 2025 accompanying biosimilar entry.
- Revenue projections remain strong but will slow as patent protections expire and competition intensifies.
FAQs
1. When will biosimilars for EYLEA enter the market?
Biosimilars are anticipated to launch between 2025 and 2027 in the U.S. and Europe, depending on regulatory approvals and patent litigation outcomes.
2. How will biosimilars affect EYLEA's price?
Introduction of biosimilars can reduce the price by 20–30%, driven by competition and payer negotiations.
3. What are the main competing drugs for EYLEA?
Lucentis, Beovu, and Faricimab are key competitors, with similar efficacy and different dosing intervals.
4. What impact will regulatory changes have on pricing?
Stricter pricing policies and value-based reimbursement models could exert downward pressure on injectable biologic prices.
5. Is there potential for EYLEA to maintain its market share?
Continued adoption of extended dosing schedules and approved indications can help preserve market share temporarily, but long-term depends on biosimilar developments.
References
[1] Market Research Future. (2022). Ophthalmic Drugs Market Report.
[2] Grand View Research. (2023). Diabetic Retinopathy Market Size & Trends.
[3] FDA. (2011). EYLEA (aflibercept) injection approval.
[4] IQVIA. (2023). Pharmaceutical Market Data.
[5] EvaluatePharma. (2023). Global Oncology & Ophthalmology Market Forecast.
